Lucas Arruda
CSO CuraCell Holding AB
Lucas has 10+ years of experience in research and development from both academia and the Biotech industry. He is a specialist in Cancer Immunotherapy, with expertise in TCR-Ts, TILs, CAR-T and Bispecific Antibodies from the Karolinska Institute, Department of Clinical Science Intervention and Technology. Before joining CuraCell he was the Head of Virus Core & Specimen Core Leader at Anocca AB. Born in 1988, holds a PharmD and PhD in Basic and Applied Immunology from the University of São Paulo.
Seminars
As the field moves beyond melanoma, the need for optimized efficacy and safety is forcing a rethink of manufacturing strategies and delivery strategies.
This workshop addresses the growing recognition that current TIL strategies involve bulk TIL expansion, diluting tumor reactive potential and requiring high dose IL-2 for efficacy.
Key questions addressed in this workshop:
- Which tumor-infiltrating lymphocyte subsets are truly reactive rather than expanded bystanders?
- Do selection approaches such as PD-1 or neoantigen targeting enrich potency or accelerate exhaustion?
• How can next-generation approaches optimize safety vs. efficacy?
- Demonstrating initial clinical feasibility of TIL therapy in colorectal and prostate cancer
- Exploring patient selection and tumor sourcing challenges in low immunogenic indications
- Translating early treatment experience into future trial design decisions
